Press Releases
Oct 18, 2024
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer

VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct....

Oct 10, 2024
FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device

iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that the U.S. Food and Drug Administration (FDA)...

Oct 10, 2024
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS)...

EXPLORE ALL US PRESS RELEASES

Articles
Jul 18, 2024
Astellas Legal and IP Division Takes Action to Advance Diversity, Equity and Inclusion

Diversity, equity and inclusion (DEI) have always been critically important to the Astellas Legal and IP Division. Since 2017, the Astellas Legal and IP Division has actively worked to promote DEI...

Feb 8, 2024
From Recurrence to Perseverance: Jim's Prostate Cancer Story

As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during...

Dec 15, 2023
Astellas Recognized for its Support of the LGBTQ+ Community through Human Rights Campaign Foundation’s Annual Corporate Equality Index

Astellas is proud to be featured on the Human Rights Campaign Foundation’s (HRC) annual Corporate Equality Index (CEI) for its continued support of the LGBTQ+ community within the workplace....

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products